inked an agreement worth up to $25 million with Meiji
Seika Kaisha to develop and commercialize pro-cognitive schizophrenia
drugs. Meiji Seika's payment covers costs of the joint development as well as any royalties from sales within Asia
. Acadia will retain rights to develop and commercialize the product in U.S. and Europe, although Meiji Seika is eligible for a portion of the revenues.
The compounds to be developed, which combine muscarinic m1 agonism with dopamine and serotonin receptor antagonism, have demonstrated pro-cognitive and antipsychotic activity in preclinical behavior models, says Acadia. The venture will enable the companies to initiate IND-enabling studies and jointly develop the treatment through to the completion of proof-of-concept clinical studies.
"We are delighted to establish this innovative partnership with Meiji Seika," says Uli Hacksell, Ph.D., Acadia CEO. "With its strong development and commercial capabilities and focus on CNS disorders, we believe Meiji Seika is an excellent partner to help advance the development of this exciting program and to commercialize in Japan and other Asian markets."